Cargando…
Regorafenib-Induced Hand–Foot Skin Reaction Is More Severe on the Feet Than on the Hands
Regorafenib is a multikinase inhibitor for the treatment of metastatic colorectal cancer. Regorafenib-induced hand–foot skin reaction (HFSR) is a common side effect during treatment. The reported frequency of HFSR was 80% (grade 3: 28%) in the Japanese subpopulation in the CORRECT trial; however, mo...
Autores principales: | Nonomiya, Yuma, Yokokawa, Takashi, Kawakami, Kazuyoshi, Kobayashi, Kazuo, Aoyama, Takeshi, Takiguchi, Tomomi, Sugisaki, Takahito, Suzuki, Kenichi, Suenaga, Mitsukuni, Wakatsuki, Takeru, Yamaguchi, Kensei, Sugimoto, Yoshikazu, Hama, Toshihiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cognizant Communication Corporation
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848261/ https://www.ncbi.nlm.nih.gov/pubmed/29914591 http://dx.doi.org/10.3727/096504018X15291727589740 |
Ejemplares similares
-
Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019) -
Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2017) -
Association Between Regorafenib Dose and Efficacy Against Metastatic
Colorectal Cancer in a Real-World Setting
por: Hatori, Masahiro, et al.
Publicado: (2021) -
Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: a single-arm trial
por: Nishizawa, Aya, et al.
Publicado: (2023) -
Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2016)